Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amphetamine-Related Disorders Clear all
Completed Phase 2 Interventional Results available

Study of Medical Treatment for Methamphetamine Addiction

NCT00833443
View directory record Official record
Conditions
Methamphetamine, Amphetamine Dependence, Pharmacogenetics, Methamphetamine Dependence, Substance Abuse
Interventions
Bupropion
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

Effects of Stimulant Dependence on Human Striatal Dopamine System - 15

NCT00000350
View directory record Official record
Conditions
Amphetamine-Related Disorders, Tobacco Use Disorder
Interventions
radioactive substance
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Lobeline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

NCT00265278
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Modafinil
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

NCT00089440
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Aripiprazole
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Withdrawn No phase listed Observational

Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates

NCT00865332
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

NCT02144415
View directory record Official record
Conditions
Healthy Volunteers, Drug Users
Interventions
EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Change the Cycle: An RCT to Prevent Injection Initiation

NCT02774954
View directory record Official record
Conditions
Substance Abuse, Intravenous, HIV, Heroin Dependence, Opioid Dependence, Cocaine Dependence, Amphetamine Dependence
Interventions
Change the Cycle
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

NCT00856323
View directory record Official record
Conditions
Amphetamine-Related Disorders, HIV, HIV Infections
Interventions
Truvada, CM
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Stimulant Abuser Groups to Engage in 12-Step

NCT00573183
View directory record Official record
Conditions
Drug Abuse
Interventions
STAGE-12, Treatment as Usual
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Jacksonville, Florida • Kaneohe, Hawaii • Columbus, Ohio + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3

NCT00000306
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Dextroamphetamine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR

NCT05380440
View directory record Official record
Conditions
Opioid-Related Disorders, Stimulant-Related Disorder, Child Neglect, Mental Health Impairment
Interventions
Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR), Standard Case Management and Referral
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
16 Years to 30 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

NCT05790239
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
Drug · Behavioral
Lead sponsor
Stephen Robert Marder
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Brain Function in Response to Motivational Stimuli

NCT00047866
View directory record Official record
Conditions
Drug Dependence
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 2 Interventional

A Dose Ranging Study of Modafinil for Methamphetamine Dependence

NCT00630097
View directory record Official record
Conditions
Substance Dependence, Amphetamine Dependence
Interventions
modafinil
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

NCT01888835
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Mirtazapine, Placebo
Drug
Lead sponsor
Phillip Coffin, MD, MIA
Government
Eligibility
18 Years to 69 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

NCT00033072
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NCT00377299
View directory record Official record
Conditions
Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions
Citicoline, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Oct 21, 2026, 6:40 PM EDT